A Study of Adaptive Radiotherapy of Head-neck Cancer Using Daily Replanning and Optimization of the Treatment Plan.
DART-HN - Daily Adaptive Radiotherapy of Head-neck Cancer.
Rigshospitalet, Denmark
40 participants
Nov 21, 2023
INTERVENTIONAL
Conditions
Summary
Radiotherapy of head-neck cancer is associated with significant side effects. Using daily online adaptive radiotherapy to account for the changing anatomy, radiation to organs at risk can be lowered. We will investigate whether this is feasible and associated with a reduction in the risk of toxicity.
Eligibility
Inclusion Criteria1
- Patients with histologically proven squamous cell carcinoma of the pharynx or larynx planned for primary radiotherapy with curative intent No current or earlier malignancies, which may influence treatment, evaluation or outcome of the head-neck cancer Informed consent as required by law The patient cannot participate in conflicting protocols Stage I-IV (excluding T1-T2N0 carcinoma of the glottic larynx) ECOG/WHO performance status 0-2
Exclusion Criteria3
- Patient with cancers of the glottic larynx (stage I/II), skull base, sino-nasal area and unknown primary tumor.
- Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic Distant metastasis Previous radiotherapy of the head and neck Previous surgery for the primary cancer with curative intent
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The patients will undergo daily online adaptive re-optimisation of the radiotherapy treatment plan following daily recontouring.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07506902